Stockscreener 앱 받기
26.99
5.70%
-1.63
시간 외 거래:
28.05
1.06
+3.93%
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant falls on late-stage trial setback for TED therapy - MSN
Wall Street analysts predict a 55.04% upside in Immunovant (IMVT): Here's what you should know - MSN
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Immunovant (NASDAQ:IMVT) CFO Tiago Girao Sells 25,760 Shares - MarketBeat
Immunovant CFO Tiago Girao sells $763,011 in company stock By Investing.com - Investing.com India
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock - MarketBeat
Immunovant CFO Tiago Girao sells $763,011 in company stock - Investing.com
Immunovant (IMVT) CFO sells 25,760 shares to cover RSU tax - Stock Titan
Immunovant (IMVT) CTO sells 2,754 shares in tax sell-to-cover - Stock Titan
IMVT Price Today: Immunovant, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Immunovant (NASDAQ:IMVT) Sets New 12-Month HighHere's What Happened - MarketBeat
Immunovant (IMVT) Innovation Pipeline | Immunovant posts 16.3% EPS beat on narrower lossRating Downgrade - Xã Thanh Hà
How Immunovant Inc. (IMVT) Affects Rotational Strategy Timing - Stock Traders Daily
Immunovant Inc stock (US45258Q1058): Is its autoimmune pipeline strong enough to unlock new upside? - AD HOC NEWS
Immunovant: Best-In-Class Ambitions, Still Unproven (NASDAQ:IMVT) - Seeking Alpha
Immunovant Inc stock (US45258Q1058): Is its autoimmune pipeline strong enough to unlock biotech upsi - AD HOC NEWS
Immunovant (NASDAQ:IMVT) Reaches New 12-Month HighShould You Buy? - MarketBeat
Immunovant stock hits 52-week high at 29.26 USD By Investing.com - Investing.com Australia
Immunovant stock hits 52-week high at 29.26 USD - Investing.com
Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $66 - Moomoo
IMVT Maintained by Goldman Sachs -- Price Target Raised to $32 - GuruFocus
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up - TipRanks
Immunovant (IMVT) CTO stout sells $251k in shares By Investing.com - Investing.com Canada
Van Tuyl, Immunovant’s chief legal officer, sells $128k in IMVT stock - Investing.com India
Insider Selling: Immunovant (NASDAQ:IMVT) Insider Sells 5,165 Shares of Stock - MarketBeat
Jay Stout Sells 10,132 Shares of Immunovant (NASDAQ:IMVT) Stock - MarketBeat
Immunovant (IMVT) CTO stout sells $251k in shares - Investing.com
Immunovant (IMVT) CLO sells 5,165 shares to cover RSU tax bill - Stock Titan
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
Immunovant (NASDAQ: IMVT) CTO sells 10,132 shares for RSU tax obligations - Stock Titan
(IMVT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Immunovant (IMVT) grants director Frank Torti RSUs and stock options - Stock Titan
Immunovant (IMVT) director receives RSU and stock option grants - Stock Titan
Immunovant (IMVT) grants director Douglas J. Hughes RSUs and stock options - Stock Titan
Immunovant (IMVT) director granted options and RSUs in new equity awards - Stock Titan
Immunovant (IMVT) awards RSUs and stock options to director Jake Bauer - Stock Titan
Immunovant (IMVT) director receives 13,880 RSUs and 7,061 options - Stock Titan
Immunovant (IMVT) COO receives new stock options and RSU grants - Stock Titan
Immunovant (IMVT) CTO granted 96,851 options and 66,937 RSUs - Stock Titan
Immunovant (IMVT) CLO receives 59,820 options and 41,343 RSUs - Stock Titan
Immunovant (IMVT) CEO awarded new stock options and RSUs in equity grant - Stock Titan
Immunovant (IMVT) CFO awarded RSUs and 94,002 options under 2019 plan - Stock Titan
Wolfe Research Maintains Immunovant(IMVT.US) With Buy Rating, Announces Target Price $47 - Moomoo
IMVT Shares Drop 2.4% After Batoclimab Fails to Meet Key Goals in Final-Stage Trial - Bitget
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - Yahoo Finance
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $42 - Moomoo
0.29%
0.00%
자본화:
|
볼륨(24시간):